References
- 1. European Medicines Agency (EMA). Guideline on good pharmacovigilance practices (GVP) Module VI – Collection, management and submission of reports of suspected adverse reactions to medicinal products (Rev 2). 2017.
- 2. Rymarczuk A, Bielski M, Lozak K, Ochyra B, Szewczyk M, Miernecka D, et al) Dobór czasopism medycznych wydawanych w Polsce dla celów przeglądów lokalnej literaratury medycznej w zakresie bezpieczeństwa stosowania produktów leczniczych. – Standard Polskiego Towarzystwa Bezpiecznej Farmakoterapii (PTBFarm). Biuletyn Bezpieczenstwa Produktow Leczniczych. 2020;15(1).
- 3. Ferguson J, Mockbee C, Erbele S, Muniz E. Evaluation of Published Case Reports’ Standards and Notification. Drug Inforn l. 2002;36:303-7.
- 4. Hauben D, Aronson J. Gold Standards in Pharmacovigilance. Drug Safety. 2007;30:645-55.
- 5. Impicciatore P, Mucci M. Completeness of published case reports on suspected adverse drug reactions: evaluation of 100 reports from a company safety database. Drug Saf. 2010;33(9):765-73.
- 6. Kelly WN. The quality of published adverse drug event reports. Ann Pharmacother. 2003;37(12):1774-8.
- 7. Pontes H, Clément M, Rollason V. Safety signal detection: the relevance of literature review. Drug Saf. 2014;37(7):471-9.
- 8. EMA. 2021 Annual Report on EudraVigilance for the European Parliament, the Council and the Commission, EMA/719826/2021, 2022.
- 9. Chinoy MA, Ahmad T, Tayyab MA, Raza S. Evidence based medicine – where do articles published in local indexed journals stand? JPMn. 2009;59(1):5-9.
- 10. Kelly WN, Arellano FMmuBarnes J,-Bergman U, Edwards IR, Fernandez AM, et al. Guidelines for submitting adverse event reports for publication. Pharmacoepidemiol Drug Saf. 2007;16(5):581-7.
- 11. Shetty KD, Dalal SR. Using information mining of the medical literature to improve drug safety. I Am Med Inform Assoc. 2011;18(5): 668-74.